Latham & Watkins Advises Unnatural Products in US$45 Million Series B Financing

Unnatural Products, a biotech developing orally delivered macrocyclic peptides to address previously undruggable targets, has announced the closing of a US$45 million Series B financing led by The Venture Collective, with participation from argenx, Droia Ventures, and existing investors Merck Global Health Innovation Fund, Artis Ventures, and First Spark Ventures. The funding will support development of the company’s proprietary drug discovery platform and advance its pipeline of macrocyclic peptide therapeutics designed to address historically difficult to drug or “undruggable” targets.

Latham & Watkins LLP represented Unnatural Products in the transaction with a corporate team led by Bay Area partner Alex Kassai, with associates Chris Pham, Tori Hu, and Rachel Oh. Advice was also provided on data privacy matters by San Diego/San Francisco counsel Jennifer Howes.